MOD GRF (1-29)

MOD GRF (1-29) acts as an agonist of the GHRH receptor (GHRHR) in the anterior pituitary gland.

• Receptor binding: It specifically binds to GHRHR on somatotroph cells, activating the adenylate cyclase signaling pathway and increasing intracellular cAMP levels.
• GH release: The rise in cAMP triggers exocytosis of GH granules, resulting in a pulse of GH release into the systemic circulation.
• Somatostatin regulation: GH release is modulated by hypothalamic somatostatin, which inhibits secretion; MOD GRF (1-29) partially counteracts this inhibition.
• Effect on IGF-1: The released GH stimulates hepatic production of IGF-1, which mediates many anabolic and tissue growth effects.
• Enhanced stability: Amino acid substitutions protect the peptide from degradation by enzymes such as dipeptidyl peptidase IV (DPP-IV), prolonging its action.

• GH/IGF-1 axis research: Tool for studying the physiology of GH secretion and IGF-1 regulation.
• Anti-aging medicine: Off-label use to improve body composition, increase lean muscle mass, and reduce body fat.
• Sports recovery: Used by athletes to accelerate muscle recovery after intense exercise and improve sleep quality.
• GH deficiency therapy: Potential use in patients with GHRH deficiency, though not formally approved.

The effects of MOD GRF (1-29) are primarily mediated by increased GH and IGF-1. Reported effects include: increased lean muscle mass, reduced body fat, improved bone density, enhanced sleep quality (especially deep sleep), increased energy and vitality, improved post-exercise muscle recovery, and possible improvements in cognitive function and mood. Effects are more pronounced in individuals with low GH levels, such as older adults.

MOD GRF (1-29) is not approved by the FDA or EMA for human use, so its use is off-label or exclusively in research. Contraindications include: pregnancy, lactation, active cancer (especially GH/IGF-1-sensitive tumors), uncontrolled diabetes, and severe cardiovascular diseases. Potential adverse effects include: injection site pain or redness, fluid retention, joint pain, carpal tunnel syndrome, increased intracranial pressure (rare), and possible stimulation of tumor growth. Monitoring of IGF-1 and blood glucose levels is recommended during use. Dosage should be individually adjusted and under medical supervision.

MOD GRF (1-29) has not been approved by the FDA (USA), EMA (Europe), or any other major regulatory agency for human clinical use. It is classified as a research chemical and its use is restricted to laboratories and preclinical studies. In some countries, it may be available through compounding pharmacies for off-label use under medical prescription, but without formal approval.

Typical dosing in research and off-label use varies, but commonly ranges from 100-300 mcg, 1-3 times daily, administered subcutaneously. Some protocols recommend 200 mcg in the morning and 200 mcg at night, or 100-200 mcg before sleep to optimize the nocturnal GH peak. Dosage should be adjusted based on individual response and IGF-1 levels. It is recommended to start with low doses and gradually increase.

Lyophilized MOD GRF (1-29) should be stored in a cool, dry place, protected from light, ideally at 2-8°C (refrigerator). Once reconstituted with bacteriostatic water or saline, it should be kept refrigerated and used within 7-14 days to prevent degradation. Do not freeze after reconstitution. Avoid vigorous shaking.